# Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety

> **NCT07453862** · PHASE1 · RECRUITING · sponsor: **Beijing Friendship Hospital** · enrollment: 20 (estimated)

## Conditions studied

- Restless Leg Syndrome (RLS)
- Variant Restless Legs Syndrome

## Interventions

- **DRUG:** Crisugabalin

## Key facts

- **NCT ID:** NCT07453862
- **Lead sponsor:** Beijing Friendship Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-03-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-08-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2026-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07453862

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07453862, "Novel Calcium Channel Modulators in RLS and Variants: Efficacy & Safety". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT07453862. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*